Stockreport

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF WESTLAKE VILLAGE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Q4 2024 net product revenue for ZORYVE® (roflumilast) was $69.4 million, a 413% increase compared to Q4 of [Read more]